Navigation path

Pharmaceuticals - Union Register

  

Register of orphan medicinal products


GRANTED  

Product information

Recombinant protein derived from the saliva of the Ornithodoros moubata tick

EU orphan designation number: EU/3/16/1687   
Active ingredient: Recombinant protein derived from the saliva of the Ornithodoros moubata tick
Indication: Treatment of Guillain-Barré syndrome
Sponsor: Akari Therapeutics Plc
75 Wimpole Street, London W1G 9RS, United Kingdom

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
29/06/2016 Orphan designation EMA/OD/030/16 (2016)4128 of 27/06/2016